Applicants: Thomas M. Jessell et al.

Serial No: 10/002,278

Filed: November 2, 2001

Page 7

## In the claims:

Please amend claims 41-48 under the provisions of revised 37 C.F.R.  $\rightarrow 1.121$  as follows:

- --1. 16. (cancelled) --
- --17. (withdrawn) --
- --18. (cancelled) --
- --19. (previously presented) An isolated dorsalin-1 polypeptide comprising continuous amino acids, the sequence of which is set forth in SEQ ID NO: 9.--
- --20. (withdrawn) --
- --21. (cancelled) -
- --22. 27. (withdrawn) --
- --28. 35. (cancelled) --
- --36. 40. (withdrawn) --
- --41. (currently amended) A pharmaceutical composition comprising the isolated dorsalin-1 polypeptide of claim [[17 or]] 19 and a pharmaceutically acceptable carrier.-

Applicants: Thomas M. Jessell et al.

Serial No : 10/002,278

Filed: November 2, 2001

Page 8

--42. (currently amended) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to stimulate neural crest cell differentiation.--

- --43. (currently amended) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to regenerate a nerve cell in a subject.--
- --44. (currently amended) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to promote bone growth in a subject.--
- --45. (currently amended) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to promote wound healing in a subject.-
- --46. (currently amended) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an amount of isolated dorsalin-1 polypeptide effective to inhibit neural tumor cell growth in a subject.--
- --47. (currently amended) The pharmaceutical composition of claim 46, wherein the neural tumor is a neurofibroma.--

Applicants: Thomas M. Jessell et al.

Serial No : 10/002,278

, Filed : November 2, 2001

Page 9

--48. (currently amended) The pharmaceutical composition of claim 46, wherein the neural tumor is a Schwann cell tumor.--